Latest news with #RP-1664
National Post
25-04-2025
- Health
- National Post
Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025
Article content CAMBRIDGE, Mass. & MONTREAL — Repare Therapeutics Inc. ('Repare' or the 'Company') (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the acceptance of two abstracts for mini-oral presentation and the acceptance of four abstracts for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois. Article content Article content Mini-Oral Presentation Details: Title: Efficacy and safety of the combination PKMYT1-inhibitor lunresertib and ATR-inhibitor camonsertib in patients with ovarian and endometrial cancers: Phase I MYTHIC study (NCT04855656) Presenter: Alison M. Schram, MD, Memorial Sloan Kettering Cancer Center Session: Innovative Approaches to Key Molecular Targets Session Date and Time: Tuesday, April 29 from 2:30-4:30 p.m. CT Location: Room S406 (Vista Ballroom) Abstract Number: CT262 Article content Title: The PLK4 inhibitor RP-1664 drives centriole modulation and single agent tumor regressions in preclinical neuroblastoma models Presenter: John M. Maris, MD, Children's Hospital of Philadelphia Session: Advancing the Science of Childhood Cancers: From Bench to Bedside Session Date and Time: Sunday, April 27 from 3:00-5:00 p.m. CT Location: Room E353 C Abstract Number: 1201 Article content Poster Presentation Details: Article content Title: A dual mechanism of sensitivity to PLK4 inhibition by RP-1664 in neuroblastoma Presenter: Michal Zimmermann, PhD, Repare Therapeutics Session: Cell Cycle Effects of Anticancer Drugs Session Date and Time: Sunday, April 27 from 2:00-5:00 p.m. CT Location: Poster Section 17 Poster Number: 9 Abstract Number: 365 Article content Title: RP-1664: A potent and selective PLK4 inhibitor causing tumor regressions in TRIM37-high xenograft models of solid tumors Presenter: Anne Roulston, PhD, Repare Therapeutics Session: Kinase and Phosphatase Inhibitors 1 Session Date and Time: Monday, April 28 from 9:00 a.m-12:00 p.m. CT Location: Poster Section 21 Poster Number: 9 Abstract Number: 1734 Article content Title: Pan-cancer analysis of TRIM37 copy-number and development of fit-for-screening in situ hybridization tools Presenter: Isabel Soria-Bretones, PhD, Repare Therapeutics Session: Diagnostic Biomarkers 2 Session Date and Time: Sunday, April 27 from 2:00-5:00 p.m. CT Location: Poster Section 31 Poster Number: 2 Abstract Number: 717 Article content Title: Targeting CCNE1 amplification in gastric cancer Presenter: Sung Joo Jang, Columbia University Irving Medical Center Session: Protein Kinases and Phosphatases as Targets for Therapy Session Date and Time: Wednesday, April 30 from 9:00 a.m.-12:00 p.m. CT Location: Poster Section 24 Poster Number: 4 Abstract Number: 6942 Article content A copy of each poster presentation is available on the Scientific Resources page of the Repare Therapeutics website and a copy of each mini-oral presentation will be available on the Scientific Resources page of the Repare Therapeutics website at the start of each mini-oral session. Article content Repare Therapeutics is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx ® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's clinical-stage pipeline includes RP-1664, a Phase 1 PLK4 inhibitor; RP-3467, a Phase 1 Polθ ATPase inhibitor; and lunresertib, a PKMYT1 inhibitor. For more information, please visit and follow @Reparerx on X (formerly Twitter) and LinkedIn. Article content Article content Article content Article content Article content
Business Wire
25-04-2025
- Business
- Business Wire
Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025
CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. ('Repare' or the 'Company') (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the acceptance of two abstracts for mini-oral presentation and the acceptance of four abstracts for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30, 2025, in Chicago, Illinois. Mini-Oral Presentation Details: Title: Efficacy and safety of the combination PKMYT1-inhibitor lunresertib and ATR-inhibitor camonsertib in patients with ovarian and endometrial cancers: Phase I MYTHIC study (NCT04855656) Presenter: Alison M. Schram, MD, Memorial Sloan Kettering Cancer Center Session: Innovative Approaches to Key Molecular Targets Session Date and Time: Tuesday, April 29 from 2:30-4:30 p.m. CT Location: Room S406 (Vista Ballroom) Abstract Number: CT262 Title: The PLK4 inhibitor RP-1664 drives centriole modulation and single agent tumor regressions in preclinical neuroblastoma models Presenter: John M. Maris, MD, Children's Hospital of Philadelphia Session: Advancing the Science of Childhood Cancers: From Bench to Bedside Session Date and Time: Sunday, April 27 from 3:00-5:00 p.m. CT Location: Room E353 C Abstract Number: 1201 Poster Presentation Details: Title: A dual mechanism of sensitivity to PLK4 inhibition by RP-1664 in neuroblastoma Presenter: Michal Zimmermann, PhD, Repare Therapeutics Session: Cell Cycle Effects of Anticancer Drugs Session Date and Time: Sunday, April 27 from 2:00-5:00 p.m. CT Location: Poster Section 17 Poster Number: 9 Abstract Number: 365 Title: RP-1664: A potent and selective PLK4 inhibitor causing tumor regressions in TRIM37-high xenograft models of solid tumors Presenter: Anne Roulston, PhD, Repare Therapeutics Session: Kinase and Phosphatase Inhibitors 1 Session Date and Time: Monday, April 28 from 9:00 a.m-12:00 p.m. CT Location: Poster Section 21 Poster Number: 9 Abstract Number: 1734 Title: Pan-cancer analysis of TRIM37 copy-number and development of fit-for-screening in situ hybridization tools Presenter: Isabel Soria-Bretones, PhD, Repare Therapeutics Session: Diagnostic Biomarkers 2 Session Date and Time: Sunday, April 27 from 2:00-5:00 p.m. CT Location: Poster Section 31 Poster Number: 2 Abstract Number: 717 Title: Targeting CCNE1 amplification in gastric cancer Presenter: Sung Joo Jang, Columbia University Irving Medical Center Session: Protein Kinases and Phosphatases as Targets for Therapy Session Date and Time: Wednesday, April 30 from 9:00 a.m.-12:00 p.m. CT Location: Poster Section 24 Poster Number: 4 Abstract Number: 6942 A copy of each poster presentation is available on the Scientific Resources page of the Repare Therapeutics website and a copy of each mini-oral presentation will be available on the Scientific Resources page of the Repare Therapeutics website at the start of each mini-oral session. About Repare Therapeutics Inc. Repare Therapeutics is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx ® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company's clinical-stage pipeline includes RP-1664, a Phase 1 PLK4 inhibitor; RP-3467, a Phase 1 Polθ ATPase inhibitor; and lunresertib, a PKMYT1 inhibitor. For more information, please visit and follow @Reparerx on X (formerly Twitter) and LinkedIn.
